Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)

References

• Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366–73.
   PubMed Web of Science ®Google Scholar
• Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236–44.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–20.
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011;29:4491–7.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273–83.
   PubMed Web of Science ®Google Scholar
• Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012;4: CD006243.
   PubMed Web of Science ®Google Scholar
• Perez EA. Cardiac toxicity of ErbB2-targeted therapies: What do we know?Clin Breast Cancer 2008;8(Suppl 3):S114–20.
   Web of Science ®Google Scholar
• Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Goss P. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 2012;60:2504–12.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol 2012;30:11–8.
   PubMed Web of Science ®Google Scholar
• Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010;119:53–61.
   PubMed Web of Science ®Google Scholar
• Rydén L, Haglund M, Bendahl PO, Hatschek T, Kolaric A, Kovács A, et al. Swedish Her2 Analysis Group. Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: A national survey performed at pathology departments in Sweden. Acta Oncol 2009;48: 860–6.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–72.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;53:1673–84.
   Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Asola R, et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial. Lancet Oncol 2009;10:1145–51.
   PubMed Web of Science ®Google Scholar
• Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol 2012;23:1164–9.
   PubMed Web of Science ®Google Scholar
• O´Shaughnessy J, Stokoe PD, Pippen Jr J, Blum JL, Krekow L, Holmes FA, et al. First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. Cancer Res 2010;70:85s (abstract).
   Web of Science ®Google Scholar
• Jiang Y, Yin W, Zhou L, Yan T, Zhou Q, Du Y, et al. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: A meta-analysis. PLoS One 2012;7:e32474.
   Google Scholar
• Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, et al. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 2012;30:930–5.
   PubMed Web of Science ®Google Scholar
• Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. Trastuzumab for patients with axillary node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:6129–34.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533–43.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Piccart-Gebhart MJ, Procter M, de Azambuja E, Weber HA, Untch M, et al. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with early HER2-positive breast cancer at 8 years of median follow-up. Cancer Res 2012;72(24 Suppl):103S–4S (abstract).
   Google Scholar
• Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol 2011;50: 344–52.
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jönsson B, Rehnberg C. Cost- effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 2008;47:1018–28.
   PubMed Web of Science ®Google Scholar
• Pivot X, Romieu G, Bonnefoi H, Pierga J-Y, Kerbrat P, Guastalla J-P, et al. PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Res 2012;72(24 Suppl.):104S (abstract).
   Google Scholar
• Untch M, Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:1090–6.
   PubMed Web of Science ®Google Scholar